Valuation: SOPHiA GENETICS SA

Market Cap 489M 428M 395M 363M 687M 47.13B 699M 4.72B 1.85B 23.02B 1.84B 1.8B 79.46B P/E 2026 *
-6.42x
P/E 2027 * -8.39x
Enterprise Value 489M 428M 395M 363M 687M 47.13B 699M 4.72B 1.85B 23.02B 1.84B 1.8B 79.46B EV / Sales 2026 *
5.24x
EV / Sales 2027 * 4.35x
Free-Float
76.86%
Yield 2026 *
-
Yield 2027 * -
1 day+0.50%
1 week+1.21%
Current month+0.40%
1 month+10.13%
3 months+12.61%
6 months+8.70%
Current year+28.87%
1 week 4.94
Extreme 4.94
5.05
1 month 4.56
Extreme 4.56
5.2
Current year 3.46
Extreme 3.46
5.2
1 year 3.34
Extreme 3.34
5.2
3 years 2.08
Extreme 2.08
5.2
5 years 2.08
Extreme 2.08
5.2
10 years 2.08
Extreme 2.08
5.2
Manager TitleAgeSince
Chief Executive Officer 46 01/07/2026
Director of Finance/CFO 64 05/11/2024
Chief Tech/Sci/R&D Officer - 10/01/2022
Director TitleAgeSince
Chairman 47 22/06/2026
Director/Board Member 57 01/06/2014
Chairman 61 01/02/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.50%+1.21% - - 489M
+1.91%+4.04%-30.13%-5.42% 32.06B
-3.46%-5.05%-43.38%+183.84% 14.18B
-1.54%-2.55%-24.35%+66.69% 5.58B
-4.70%-6.31% - - 2.24B
+0.38%+3.09%+69.19%-35.06% 2.14B
-2.91%-13.10% - - 1.75B
-4.23%-2.47%-38.47% - 1.11B
+3.95%-7.78%+51.44%+112.56% 936M
+2.30%+10.22%-36.31%-53.65% 814M
Average -1.13%-2.86%-7.43%+44.83% 6.76B
Weighted average by Cap. -2.02%-1.02%-28.04%+50.11%

Financials

2026 *2027 *
Net sales 93.4M 81.64M 75.5M 69.28M 131M 9B 133M 900M 354M 4.4B 351M 343M 15.17B 112M 98.23M 90.84M 83.36M 158M 10.83B 161M 1.08B 426M 5.29B 422M 413M 18.26B
Net income -64.65M -56.51M -52.26M -47.96M -90.76M -6.23B -92.34M -623M -245M -3.04B -243M -237M -10.5B -50.72M -44.34M -41M -37.63M -71.21M -4.89B -72.45M -489M -192M -2.39B -190M -186M -8.24B
Net Debt - -
Logo SOPHiA GENETICS SA
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
Employees
415
Date Price Change
17/07/26 EUR 5.000 -0.99%
16/07/26 EUR 5.050 +1.00%
15/07/26 EUR 5.000 +1.21%
14/07/26 EUR 4.940 -1.20%
13/07/26 EUR 5.000 +1.21%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.830USD
Average target price
8.000USD
Spread / Average Target
+37.22%

Quarterly revenue - Rate of surprise